Description (TB500)

Thymosins are small proteins found in many animal tissues. The name derives from the fact that they were first isolated from the thymus, but today we know that they are widespread in many parts of the body. Some thymosins—in particular Thymosin α1 and Thymosin β4 —are of interest for their potential medical applications, with uses that in some cases have already reached the clinical setting.

TB500 is a short peptide (a fragment) related to Thymosin Beta 4: it is often marketed as if it were the same molecule, but it is not identical to the complete Thymosin Beta 4. In the body, Thymosin Beta 4 can be released by the thymus (more active in children) and is also produced locally by various cells; It is also found in significant concentrations in certain cellular compartments and in secretions associated with wounds. Experimental studies suggest that Thymosin Beta 4 may support various tissue repair processes, promoting cell migration and contributing to the modulation of inflammation.

The TB500 sequence corresponds to the region considered "functionally active" in Thymosin Beta 4 and may share many of its properties, with the advantage of being simpler and cheaper to produce. For this reason, TB500 is often associated with supporting recovery in cases of tissue stress and injury, with particular interest in the sports world for managing post-training recovery.

---

Mechanism of action (summary)

Among thymosins, Thymosin Beta 4 is one of the most abundant and studied. It is a peptide capable of bindingto actin, influencing actin polymerization and therefore cell migration —an important process for angiogenesis and tissue regeneration. In several experimental models, Thymosin Beta 4 has also been associated with cardioprotective properties, potential support for angiogenesis in ischemic conditions, and cellular mechanisms related to survival in response to stress.

Still in the experimental field, effects on the following have been explored:

• repair of damaged tissues and modulation of inflammation

• angiogenesis and regenerative response

• differentiation and migration of cells involved in repair

---

Wound and soft tissue healing

Following injury, Thymosin Beta 4 can be released from platelets, macrophages, and other cells, helping to limit further damage and support repair processes. It has been linked to:

• reduction in apoptosis and inflammation

• support for cell migration and the formation of new blood vessels

• possible reduction of fibrosis and scarring through modulation of myofibroblasts

In this context, TB500 is often cited as an experimental treatment for muscle, tendon, and ligament injuries, especially when inflammation and slow recovery are an issue. It is also mentioned for its possible role in reducing adhesions and tissue stiffness that can limit mobility.

---

View (experimental scope)

In ophthalmology, Thymosin Beta 4 and related peptides have been studied for conditions such as dry eye and neurotrophic keratopathy, with results that, in some contexts, have indicated improvements in symptoms and corneal healing.

---

Cardiovascular and nervous systems (experimental setting)

Several preclinical studies have explored the use of Thymosin Beta 4 to support:

• regeneration and remodeling of cardiac tissue after ischemia or damage

• angiogenesis in the myocardium and reduction of fibrosis

• protection and recovery in neurological models (e.g., ischemia/stroke)

Clinical data on Thymosin Beta 4 are also available in various contexts, but the application, protocols, and definitive conclusions depend on the indication and type of formulation studied.

---

Hair (experimental field)

In animal models, Thymosin Beta 4 has been hypothesized to play a role in hair follicle biology, with potential influence on cell migration/differentiation and hair growth cycles. There are many testimonials circulating online, but they are no substitute for solid clinical evidence.

---

Reported effects (summary)

• Support for the recovery of muscles, tendons, ligaments, skin

• Anti-inflammatory action (in experimental settings)

• Support for angiogenic and reparative processes

• Potential interest for skin, cornea, cardiovascular system, and CNS (preclinical)

---

Possible side effects

• Redness or pain at the injection site (if used in injectable form)

---

Preparation of the solution (reconstitution)

To reconstitute a lyophilized powder:

1. Inject the diluent by running the liquid down the side of the vial (not directly onto the powder).

2. Stir gently until completely dissolved (do not shake).

3. The solution must be clear.

Do not mix different peptides in the same syringe, as this increases the risk of molecule degradation.

---

Storage

After reconstitution, store in a refrigerator at 2–8°C. The solution can generally be stored for approximately 21 days; the shelf life may be extended if bacteriostatic water is used (if specified by the product).